StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) KPIs and segments

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$577.34−6.76 (-1.16%)

Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của United Therapeutics · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của United Therapeutics: 43 chỉ số vận hành, trong đó có Top Specialty Distributor #1, Top Specialty Distributor #2 và Gross-to-Net Accrued Deductions Liability, lấy từ 77 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Tyvaso DPI($M)2
327330339336315303273275258228214
United States($M)
327330338336315303273275258228214
ROW($M)
000.3000.4000.400000
Remodulin($M)2
126127128126135138135128147128115
United States($M)
99.4109104111114120118115123108106
ROW($M)
26.917.823.715.2211816.512.924.819.78.80
Nebulized Tyvaso($M)2
126127126142154164143159140145137
United States($M)
110113119134141139136145130134124
ROW($M)
16.314.66.807.9013.925.26.30149.7011.313.2
Orenitram($M)2
12613612113112412110811310710684.1
United States($M)
12613612113112412110811310710684.1
ROW($M)
00000000000
Unituxin($M)2
65.253.662.347.958.458.267.561.151.758.454.2
United States($M)
594955.946.555.456.961.857.646.853.448.7
ROW($M)
6.204.606.401.4031.305.703.504.9055.50
Other($M)2
6.805.306.606.905.5055.505.504.906.203.90
United States($M)
6.5056.406.7054.704.204.304.6062.60
ROW($M)
0.300.300.200.200.500.301.301.200.300.201.30
Adcirca($M)2
6.702.907.809.706.5064.7075.706.406.80
United States($M)
6.702.907.809.706.5064.7075.706.406.80
ROW($M)
00000000000
United States($M)
734744753775760750706717675642586
ROW($M)
49.737.337.424.738.844.830.231.639.736.228.8
Tyvaso DPI($M)
276247280281267254235236221194183
Orenitram($M)
1201281141241171121021061019778.9
Nebulized Tyvaso($M)
117119119135149155135150132136128
Remodulin($M)
109111120113120124121115135120103
Unituxin($M)
63.248.656.444.355.65365.356.347.954.849.2
Adcirca($M)
3.701.904.405.303.803.402.903.903.103.804.10
Other($M)
-4.20-6.80-7.40-4.10-1.50-1-1.50-0.30-1.80-1.20-2.20
Top Specialty Distributor #1 — Share of Total Revenues(%)
50.0%48.0%52.0%52.0%51.0%52.0%52.0%51.0%51.0%
Top Specialty Distributor #2 — Share of Total Revenues(%)
40.0%37.0%35.0%37.0%36.0%34.0%34.0%36.0%34.0%
Gross-to-Net Accrued Deductions Liability (Ending Balance)($M)4
241270248258206195178160137133131126
Rebates & Chargebacks Accrued Liability($M)
220251229239188174159141117116114108
Specialty Distributor Fees Accrued Liability($M)
13.81211.511.711.711.911.411.611.89.408.9010.4
Prompt Pay Discounts Accrued Liability($M)
6.7065.706.305.607.306.305.106.305.605.505.30
Allowance for Product Sales Returns($M)
0.7011.301.401.301.601.302.202.401.902.301.90
Gross-to-Net Provisions — Current-Period Sales($M)4
185167172
Gross-to-Net Provisions — Prior-Period Reserve Adjustments($M)4
-5.70-5.40-5.90
Gross-to-Net Payments & Credits Applied — Current-Period Sales($M)3
37.135.238.1
Gross-to-Net Payments & Credits Applied — Prior-Period Sales($M)4
171104138
Total Tyvaso Franchise Net Product Sales (DPI + Nebulized)($M)3
504453458464478470466416434398373351
Total Tyvaso Franchise — U.S. Net Product Sales($M)
496436443457470455441409420389361337
Total Tyvaso Franchise — Rest-of-World (ROW) Net Product Sales($M)
7.6016.314.67.107.9014.325.26.70149.7011.313.2
Total Tyvaso Franchise — Reported YoY Revenue Change(%)
5.0%-4.0%-2.0%12.0%10.0%18.0%25.0%19.0%33.0%25.0%56.0%45.0%
Tyvaso DPI Net Product Sales($M)4
379327330339336315303273275258228214
Tyvaso DPI — Reported YoY Revenue Change(%)
13.0%4.0%9.0%24.0%22.0%22.0%33.0%28.0%34.0%33.0%92.0%132.0%
Tyvaso DPI — Product Cost of Sales($M)
49.951.183.258.755.348.548.138.439.137.633.330.8
Tyvaso DPI — Inventory Write-Downs($M)
0.407.9039.29.605.105.80
Tyvaso DPI — Commercial Supply Firm Purchase Commitment Loss($M)
0.107.5026.8
Nebulized Tyvaso Net Product Sales($M)2
125126127126142154164143159140145137
Nebulized Tyvaso — Reported YoY Revenue Change(%)
-12.0%-18.0%-22.0%-12.0%-11.0%10.0%13.0%4.0%32.0%12.0%21.0%-9.0%
Nebulized Tyvaso — Product Cost of Sales($M)
6.508.908.606.406.705.608.507.409.408.408.909
Orenitram Net Product Sales($M)2
14512613612113112412110811310710684.1
Orenitram — Reported YoY Revenue Change(%)
11.0%1.0%12.0%12.0%16.0%16.0%14.0%28.0%23.0%13.0%20.0%11.0%
Orenitram — Product Cost of Sales($M)
8.506.107.406.906.806.708.305.707.605.909.205.20
Remodulin Net Product Sales (Incl. Remunity Pumps)($M)2
122126127128126135138135128147128115
Remodulin — Reported YoY Revenue Change(%)
-3.0%-6.0%-8.0%-5.0%-2.0%-9.0%8.0%17.0%-2.0%16.0%5.0%-6.0%
Remodulin — Product Cost of Sales($M)
1617.416.18.1013.114.313.813.413.312.87.9012.2
Unituxin Net Product Sales (High-Risk Neuroblastoma)($M)2
52.365.253.662.347.958.458.267.561.151.758.454.2
Unituxin — Reported YoY Revenue Change(%)
9.0%12.0%-8.0%-8.0%-22.0%13.0%0.0%25.0%19.0%17.0%19.0%48.0%
Unituxin — Product Cost of Sales($M)
5.10255.903.602.805.202.204.803.803.605
Adcirca Net Product Sales($M)2
4.506.702.907.809.706.5064.7075.706.406.80
Adcirca — Reported YoY Revenue Change(%)
-54.0%3.0%-52.0%66.0%39.0%14.0%-6.0%-31.0%-4.0%-24.0%-12.0%-35.0%
Adcirca — Product Cost of Sales($M)
2.10313.404.402.702.601.803.102.602.602.70
Other Product & Service Revenues($M)2
4.906.805.306.606.905.5055.505.504.906.203.90
United States Consolidated Net Product & Service Revenues($M)1
809734744753775760750706717675642586
Consolidated Revenues — Reported YoY Change(%)
4.0%-2.0%-2.0%7.0%7.0%12.0%17.0%20.0%23.0%20.0%34.0%25.0%
TETON-PPF Phase 3 Trial Enrollment Progress (Progressive Pulmonary Fibrosis)(%)
100.0%95.0%75.0%
Research & Development Expense (MD&A Disaggregation by Nature)($M)4
279146138140128134149134104140104151
External R&D (Clinical Sites, CROs & Pre-Approval CMOs)($M)1
77.171.257.862.763.562.457.263.751.749.452.750.4
External R&D — Reported YoY Change(%)
21.0%14.0%1.0%-2.0%23.0%26.0%9.0%26.0%10.0%0.0%17.0%8.0%
Internal R&D (Personnel, Pre-Approval Mfg & Lab Facilities)($M)1
615458.357.350.855.948.350.343.944.544.943.2
Internal R&D — Reported YoY Change(%)
20.0%-3.0%21.0%14.0%16.0%26.0%8.0%16.0%28.0%28.0%31.0%22.0%
Other R&D (IPR&D Acquisitions, Upfront Licenses & Milestones)($M)
13010.216.710.64.807.6036.613.10.5037.10.1052.1
R&D Share-Based Compensation Expense($M)
11.110.95.408.908.408.106.906.707.408.606.405.70
Selling, General & Administrative Expense (MD&A Disaggregation)($M)3
146207184191183213170169219178144132
Cost of Sales Excluding Share-Based Compensation($M)1
9898.513210210086.691.674.881.875.971.870.1
Cost of Sales Share-Based Compensation Expense($M)
1.10111.100.9010.901.101.301.901.100.90
Inventories by Manufacturing Stage (Total Net)($M)4
202194178183177169165158147137120112
Raw Materials Inventory($M)
35.632.234.630.631.232.734.128.623.72221.621.7
Work-in-Process (WIP) Inventory($M)
37.437.535.135.334.833.534.334.332.834.434.834.4
Finished Goods Inventory($M)
129124109117111103979590.280.163.855.7
Total Inventory Write-Downs Recognized($M)
11.419.244.911.66.509
Gross Property, Plant & Equipment — Commercial & Organ Manufacturing Buildout($M)6
2,6782,5422,4302,2982,1041,8941,8131,7141,6321,5561,5171,474
Construction in Progress (Warp-10 & DPF Xenotransplant Facilities)($M)
76779470459344032927721817611096.8259
Buildings, Cleanrooms & Leasehold Improvements (Gross)($M)
1,054955950945917889869864852852837685
Laboratory, Bioprocessing & Manufacturing Equipment (Gross)($M)
537517510494484483475450441441431381
Owned Land & Campus Acreage Carrying Value($M)
321276267267264193193182163153152148
Advance Payments on Manufacturing Equipment($M)
3.500.705.70-5.105.700.609.20617.80.404.308.70
Accumulated Depreciation($M)
636612589568549531511491476461443428
Share-Based Compensation Expense by Award Vehicle($M)4
4143.433.93939.137.831.82741.749.725.616.6
Restricted Stock Units (RSUs) Expense($M)
29.129.721.526.627.12623.417.827.219.215.514.1
Stock Options Expense($M)
1112.811.511.411.311.18.50888.105.702.90
Employee Stock Purchase Plan (ESPP) Expense($M)
0.900.900.9010.700.700.700.600.600.500.500.50
Share Tracking Awards Plan (STAP) Cash-Settled Phantom Award Expense($M)
000000-0.800.605.9021.93.90-0.90
Stock Options Outstanding (Period-End)5
2,887,1033,535,0494,430,7744,636,3305,378,5905,655,5115,794,0375,571,5455,784,5216,024,2346,420,8636,213,853
Stock Options Exercisable
1,708,7612,348,3473,243,8723,312,3544,054,6144,339,2654,476,2714,592,7934,805,7695,029,4325,427,5815,741,239
Stock Options Weighted-Average Exercise Price($)
226207193166162160159149148146145137
Stock Options Outstanding — Aggregate Intrinsic Value($M)
9131,1851,7701,4891,3867318671,1381,2191,038546518
Unrecognized Stock Option Compensation Cost($M)
68.784.29753.364.173.384.453.7626875.925.4
Cash Proceeds from Employee Stock Option Exercises($M)
87.412668.39940.218.116.625.732.552.142.27.30
Unvested Restricted Stock Units (RSUs) Outstanding2
1,419,1031,419,2461,421,0311,416,8711,421,1731,430,1541,437,4771,219,6541,232,3761,208,7711,212,383964,759
Unvested RSUs — Weighted-Average Grant-Date Fair Value($)
315313312253253252252225225221221210
Unrecognized RSU Compensation Cost($M)
210242273165187209236157185185205133
Treasury Stock Held in Treasury (Shares)(M)2
36.335.435.032.832.830.230.230.230.230.129.926.6
Treasury Stock Carrying Cost($M)
6,1395,6455,4424,2604,2623,4753,4753,4753,4753,4443,3862,579
Cash Paid for Common Stock Repurchases (ASR & Open Market)($M)
50001,50001,000000001,0000
Available-for-Sale Marketable Debt Securities (Fair Value)($M)4
2,2511,9222,1263,0503,0193,7853,2763,0433,0312,9532,9693,757
MannKind Corporation (MNKD) — Total Revenue Earned from United Therapeutics($M)4
56.366.955.859.959.353.558.852.150.351.647.538.2
MannKind Corporation (MNKD) — Tyvaso DPI Commercial Supply Manufacturing Revenue($M)
16.529.62225.42622.228.822.623.22624.517.1
MannKind Corporation (MNKD) — Tyvaso DPI 10% Royalty Revenue($M)
37.532.432.733.633.331.2302727.125.622.721
MannKind Corporation (MNKD) — Non-Cash 1% Tyvaso DPI Royalty Sold to Sagard($M)
3.703.203.303.403.303.1032.702.70
MannKind Corporation (MNKD) — Deferred Revenue on UTHR Supply Agreement($M)2
43.444.950.451.357.255.45862.470.572.37477.5
Consolidated Total Revenues($M)2
833783782790800799794736749715678615
Cost of Sales($M)
99.199.513310310187.692.575.983.177.872.971
Gross Profit($M)
733684648687699711702660666637605544
Operating Income($M)2
308331326357389365383358343320356260
Research & Development Expense($M)
279146138140128134149134104140104151
Selling, General & Administrative Expense($M)
146207184191183213170169219178144132
Net Income($M)2
259333275364339310322301309278307217
Diluted Earnings per Share($)
5.717.275.827.166.416.636.395.856.17
Weighted-Average Diluted Shares(M)
45.345.847.247.348.348.648.447.549.7
Cash, Cash Equivalents & Short-Term Marketable Investments3
Cash & Cash Equivalents($M)
1,1891,8031,2801,5571,3401,5931,9001,6971,5541,3561,2521,208
Short-Term Marketable Investments($M)
8798598741,3631,4281,4561,4211,5701,7731,6161,4561,786
Long-Term Marketable Investments($M)
1,4681,1411,3171,7771,5671,9181,7111,4751,2791,3301,4921,910
Total Assets($M)5
7,0347,2206,7147,8807,3517,9087,7447,3647,1236,7236,4957,167
Accounts Receivable, Net($M)
349310312350298379322279342291307279
Inventories, Net($M)
202194178183177169165158147137120112
Property, Plant & Equipment, Net($M)
2,0421,9301,8411,7301,5561,3621,3031,2221,1571,0951,0741,045
Total Liabilities($M)
7588208137847617349379201,0221,0261,1571,182
Stockholders' Equity($M)
6,2766,4005,9017,0966,5907,1746,8076,4446,1015,6975,3385,985
Operating Cash Flow($M)4
307314463346562192461341377232377151
Capital Expenditures($M)
18110810117321162.274.986.776.545.138.278.7
Depreciation & Amortization($M)
26.424.222.622.821.921.119.819.719.118.71513.7
Stock-Based Compensation (Cash Flow)($M)
4143.433.93939.137.831.82741.749.725.616.6
Common Stock Repurchases (Cash Outflow)($M)
500-01,500-01,000-0-0-0-0-01,000-0

2 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: United Therapeutics Corporation (a Delaware Public Benefit Corporation) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026).
  • Core commercial & channel KPIs (Key #1 and Key #2) track U.S. specialty distributor concentration (top two distributors accounted for 50% and 40% — 90% combined — of Q3 2026 total revenues), the complete Gross-to-Net (GTN) rebate, chargeback, discount, return, and fee reserve rollforward ($241.2M accrued liability at September 30, 2026; $638.2M current-year sales provisions in FY2025 and $184.5M in Q3 2026), and complete U.S. vs. Rest-of-World net product sales, company-reported YoY percentage growth, and product-level gross profit and cost of sales across Tyvaso DPI ($378.5M, +13% YoY in Q3 2026), Nebulized Tyvaso ($125.3M, -12% YoY), Orenitram ($145.0M, +11% YoY), Remodulin ($122.0M, -3% YoY), Unituxin ($52.3M, +9% YoY), Adcirca ($4.5M), and Other ($4.9M).
  • Supply-chain & subsidiary cross-checks: Exclusive Tyvaso DPI manufacturer MannKind Corporation (NASDAQ: MNKD) independently reports quarterly commercial supply manufacturing revenue ($29.7M in Q3 2026) and its 10% contractual royalty on Tyvaso DPI net sales ($37.5M in Q3 2026, matching 9.90% of UTHR's $378.5M reported Tyvaso DPI net sales). Wholly owned UK subsidiary United Therapeutics Europe, Ltd. (#03938816) is covered via OCR-verified UK Companies House statutory balance sheets and employee counts (FY2018–FY2025). Monthly BLS pharmaceutical and biological Producer Price Indices and medical Consumer Price Indices update through October 2026.
  • Accounting & calculation discipline: United Therapeutics files consolidated U.S. GAAP financial statements only (no parent-only standalone financial statements exist). All displayed numbers are strictly as published except standalone Q4 / quarterly splits of cumulative year-to-date figures where explicitly labeled with the period-splitting formula.

Không hiện vì thiếu các kỳ gần đây (12)

  • Commercial Channel Concentration & Gross-to-Net (GTN) Reserves (Key #1) › Top Specialty Distributor #3 — Share of Total Revenues (≥10% Threshold)
  • External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › U.S. Retail Sales — Pharmacies & Drug Stores (Census MRTSSM44611USS)
  • External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Tyvaso DPI Beneficiaries
  • External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Orenitram ER Beneficiaries
  • External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Remodulin Beneficiaries
  • Financial Context (GAAP, from DB) › Total Assets › Goodwill
  • Commercial Patients Currently Treated Across Therapies — Disclosed only as a lower bound ('Over 15,500 patients') for FY2024 in the 2025 Proxy Statement, breaking annual continuity between exact/approximate point disclosures in FY2021 (~10,000), FY2022 (12,592), FY2023 (14,517), and FY2025 (~17,000).
  • Centralized Ex-Vivo Lung Perfusion (EVLP) Lung Transplant Recipients — Cumulative transplant figures are disclosed only as lower bounds in FY2024 ('Over 500 patients') and FY2025 ('Over 730 patients'), while single-year volume (179 lung transplant recipients) is disclosed only for FY2025.
  • TETON-1, TETON-2 & ADVANCE OUTCOMES Enrolled Patient Counts — Completed static trial cohort totals (598, 597, and 728 enrolled patients, respectively) rather than ongoing quarterly time-series metrics through Q3 2026.
  • Workforce Gender & Racial/Ethnic Representation (%) — Disclosed in FY2020–FY2023 Form 10-K filings (50%–52% women; 35%–36% racial/ethnic minority) but omitted from FY2024 and FY2025 Form 10-K filings.
  • United Therapeutics Europe, Ltd. Standalone Revenue & Operating Profit — Omitted from public UK Companies House filings under Section 444(5B) of the UK Companies Act 2006 small-companies filleted accounts exemption.
  • Scope 1, Scope 2 & Scope 3 Greenhouse Gas Emissions and Campus Energy/Water Volumes — Not published as a multi-year quantitative table across FY2024–FY2025 in the Corporate Responsibility & PBC Reports.

Dữ liệu cập nhật 2026-11-15.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

United Therapeutics Europe, Ltd. (UK Subsidiary #03938816)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của United Therapeutics

See a number that looks wrong?